A new study suggests that Epidiolex, a CBD-based drug approved by the FDA, could offer relief for veterans suffering from Gulf War Illness (GWI). The research, conducted on rats, indicates Epidiolex’s potential in alleviating cognitive, mood, and pain-related symptoms associated with GWI, a condition linked to chemical exposures during the 1990-1991 Gulf War.
Jazz Pharmaceuticals’ Epidiolex, a cannabidiol oral solution for treating rare forms of epilepsy, showed mixed results in a Phase 3 trial in Japan. While the trial did not achieve its primary goal of reducing seizure frequency, there were improvements in other areas, and no new safety concerns were identified. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.
